March 04, 2019
Insys Therapeutics Inc. investors urged a New York federal judge Friday to certify their putative class action accusing the pharmaceutical company of overstating its opioid spray's financial strength, a move that sparked a stock downturn once the accounting problems were revealed.
June 13, 2018
Insys Therapeutics Inc. and its top brass largely lost their bid to boot an investor's fraud suit Tuesday when a New York federal judge found the complaint had adequately tied the company's alleged misstatements to a concrete loss, allowing the proposed shareholder action accusing Insys of overstating its fentanyl spray's financial strength to move forward.
November 07, 2017
Specialty pharmaceutical company Insys Therapeutics Inc. has urged a New York federal court to toss a proposed class action accusing it of seeking to cover up declining revenues from its fentanyl-based pain medication Subsys, saying that the investors behind the suit are making a mountain out of a molehill.
June 01, 2017
The plaintiffs firm Levi & Korsinsky LLP was selected by a New York federal judge on Wednesday to represent investors who accuse Insys Therapeutics Inc. of securities fraud over a possible $5 million accounting error that the pharmaceutical company disclosed in March.
March 17, 2017
Insys Therapeutics Inc., a publicly traded company that sells and develops pain treatments for people with cancer and epilepsy, was hit with a potential securities fraud class action in New York on Friday after its stock dropped when it said it may have overstated past revenues by $5 million.